News & Events

Nerofe has received a new US patent for metastatic cancer treatment

21 Nov|

Phase2a Nerofe study has begun in Rabin and Kaplan medical centers

21 Sep|

Phase2a Nerofe study has begun in Rabin and Kaplan medical centers

PMWC 2018 conference – New Technology Presented

04 Feb|

At  PMWC 2018 conference Dr. Yoram Devary presented ISK new technology dealing with “personalized ImmunoOncology therapy” 

New Article Published: Nerofe Phase I trial summary

11 Dec|

The Phase I Nerofe (dTCApFs) human trial summary has been published in the Molecular and Clinical Oncology Journal.

In this trial Nerofe was found to be safe and well‑tolerated, and potentially efficacious as an anti-cancer agent.

Successful completion of Phase I Nerofe Trial on Solid tumors

21 Nov|

Successful completion of Phase I Nerofe Trial on Solid tumors

Nerofe Pre-clinical Paper Published in Molecular and Clinical Oncology Journal

21 Oct|

Link To Article

ISK is going to the BIO conference 2016

29 Mar|

ISK was selected for the 6th time to represent Israel in the BIO conference which is being held this year in San-Francisco.

Nerofe’s Triple Action

01 Nov|

Nerofe causes ER stress to different type of cells
NEROFE® TRIPLE-ACTION:
In Vitro assays have shown that Nerofe causes ER stress to cancer and endothelial cells, thus leading to cancer cell death and depletion of angiogenesis factors from serum, as seen in Phase Ia results. Because Immune cells express ST2 (Nerofe’s receptor), it is hypothesized

Breakthrough – Cancer Immunotherapy Effects of Nerofe

17 Sep|

NerofeTM stimulates cancer cells attraction to APC and T cells and thereby inducing the death of cancer cells.

Recent FACS results have shown a significant increase in CD86 expressing cells in three types of malignant cells treated with NerofeTM.

CD86 is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells,

ISK is going to the BIO conference 2015

23 Jun|

ISK was selected for the 5th time to represent Israel in the BIO conference in philadelphia